Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Overexpression of Vimentin in Canine Prostatic Carcinoma

Full text
Author(s):
Rodrigues, M. M. P. [1] ; Rema, A. [2] ; Gaertner, F. [3, 2] ; Soares, F. A. [4] ; Rogatto, S. R. [5] ; De Mour, V. M. B. D. [6] ; Laufer-Amorim, R. [1]
Total Authors: 7
Affiliation:
[1] Sao Paulo State Univ UNESP, Dept Clin Vet Med, Botucatu, SP - Brazil
[2] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Oporto - Portugal
[3] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Oporto - Portugal
[4] AC Camargo Hosp, Dept Pathol, Sao Paulo - Brazil
[5] Sao Paulo State Univ UNESP, Dept Urol, Botucatu, SP - Brazil
[6] Univ Fed Goias, Sch Vet Med, Goiania, Go - Brazil
Total Affiliations: 6
Document type: Journal article
Source: Journal of Comparative Pathology; v. 144, n. 4, p. 308-311, MAY 2011.
Web of Science Citations: 4
Abstract

Canine prostatic tumours exhibit similarities to those of man and may represent a useful model system to explore the mechanisms of cancer progression. Tumour progression to malignancy requires a change from an epithelial phenotype to a fibroblastic or mesenchymal phenotype. Vimentin expression is associated with the invasive phenotype of human prostate cancer cells. The aim of the present study was to characterize immunohistochemically the expression of vimentin by canine prostatic carcinomas. Primary carcinomas and metastatic tumour foci both showed vimentin expression. This finding suggests that the acquisition of the epithelial-mesenchymal transition phenotype in canine prostatic carcinoma may be characterized by the presence of mesenchymal intermediate filament (vimentin) that could lead to a higher likelihood of metastasis. Published by Elsevier Ltd. (AU)

FAPESP's process: 06/61814-1 - Canine prostatic epithelial atypia: molecular and immunophenotypic aspects
Grantee:Renee Laufer Amorim
Support Opportunities: Regular Research Grants